Printer Friendly
The Free Library
14,678,926 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

ADVENTRX Announces Positive CoFactor Study Data at AACR Special Conference in Cancer Research.


SAN DIEGO -- ADVENTRX Pharmaceuticals, Inc. (AMEX AMEX

See: American Stock Exchange
:ANX ANX Annex
ANX Adventrx Pharmaceuticals (San Diego, CA)
ANX Automotive Network Exchange (AIAG)
ANX Advanced Network Exchange
ANX Ascending Node Crossing (satellites) 
) today announced that positive preclinical data from a study with CoFactor cofactor

An atom, organic molecule, or molecular group that is necessary for the catalytic activity (see catalysis) of many enzymes. A cofactor may be tightly bound to the protein portion of an enzyme and thus be an integral part of its functional structure, or it may
(TM) in a colorectal cancer colorectal cancer

Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat.
 model were presented at the American Association for Cancer Research Wikipedia is not the place for advertisement or self-advertising.

The American Association for Cancer Research (AACR) is an organization based in Philadelphia, Pennsylvania, that focuses on all aspects of cancer research including basic, clinical and translational
 (AACR AACR American Association for Cancer Research
AACR Anglo-American Cataloging Rules
AACR Australasian Association of Cancer Registries
AACR African Armed Conflicts Resolved
) special conference in cancer research, Colorectal Cancer: Molecular Pathways and Therapies. The study suggests that CoFactor in combination with 5-fluorouracil (5-FU) and oxaliplatin may be an effective chemotherapeutic regimen against colorectal cancer, with higher efficacy and lower toxicity than the equivalent 5-FU, oxaliplatin and leucovorin regimen.

ADVENTRX's director of preclinical programs, Mark J. Cantwell, Ph.D., and chief technical officer, Joan M. Robbins, Ph.D., coauthored the study titled, "5,10-Methylenetetrahydrofolate Enhances Antitumor an·ti·tu·mor   also an·ti·tu·mor·al
adj.
Counteracting or preventing the formation of malignant tumors; anticancer.

Adj. 1.
 Activity and Reduces Toxicity of 5-Fluorouracil Plus Oxaliplatin Combination Therapy in a Colorectal Cancer Xenograph Model." The poster, presented by Dr. Cantwell in poster session A on October 20 from 5:30-7:30pm, is available via the Company's Web site at www.adventrx.com. The conference is being held from October 19-23 at the Laguna Cliffs Marriott Resort and Spa in Dana Point, Calif.

"While combination therapy with 5-FU, leucovorin and oxaliplatin has shown improved clinical efficacy in treating colorectal cancer compared with 5-FU and leucovorin, optimum efficacy with oxaliplatin combination therapy might not be achieved in this combination due to multiple factors. Among these are oxaliplatin's well characterized toxicity and that leucovorin may contribute to the severity of 5-FU's systemic toxicity," said Dr. Cantwell. "Preclinical data suggest that CoFactor as a replacement for leucovorin may result in improved overall efficacy and lower toxicity of 5-FU-containing regimens. CoFactor has already demonstrated antitumor activity with an apparent safer toxicity profile in combination with 5-FU in Phase I and Phase II clinical trials in treatment of metastatic Metastatic
The term used to describe a secondary cancer, or one that has spread from one area of the body to another.

Mentioned in: Coagulation Disorders


metastatic

pertaining to or of the nature of a metastasis.
 colorectal cancer."

About ADVENTRX

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments that improve the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability bioavailability /bio·avail·a·bil·i·ty/ (bi?o-ah-val?ah-bil´i-te) the degree to which a drug or other substance becomes available to the target tissue after administration.

bi·o·a·vail·a·bil·i·ty
n.
 and resistance. The Company's lead compound, CoFactor(TM), is a biomodulator of 5-fluorouracil (5-FU), a widely used cancer chemotherapy. CoFactor is currently being tested with 5-FU in a US-based Phase II and an EU-based Phase IIb clinical trial as a first line treatment of metastatic colorectal cancer. In addition, CoFactor has received clearance under a special protocol assessment from the FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 to begin a Phase III pivotal clinical trial for metastatic colorectal cancer. More information can be found on the Company's Web site at www.adventrx.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the US Food and Drug Administration and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's last quarterly report on Form 10-Q, as well as other reports that the Company files from time to time with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Comment:ADVENTRX Announces Positive CoFactor Study Data at AACR Special Conference in Cancer Research.
Publication:Business Wire
Geographic Code:1USA
Date:Oct 21, 2005
Words:586
Previous Article:Bernadette Mangan Named Chief Executive Officer of St. Christopher's Hospital for Children.
Next Article:Pacific Fuel Cell Corp. Announces Redemption of Convertible Debenture.
Topics:



Related Articles
Nicotine: addictive and spreads cancer?
Herpesvirus may boost AIDS expression.
New anticancer strategy targets gene. (HER-2/neu gene)
FDA, others offer new tamoxifen warnings. (Food and Drug Administration)
Cervical cancer risk rises if women HPV also have herpes infection. (Digests).
ImmunoGen, Inc. Announces Clinical and Preclinical Findings with TAP Compounds to be Presented at the AACR-NCI-EORTC International Conference on...
Gloucester Pharmaceuticals Reports on Preclinical Study of Depsipeptide in Pancreatic Cancer from the 97th Annual Meeting of The American Association...
Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session.
ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting.(Clinical report)
Telomerase Presentations at the AACR 2007 Annual Meeting.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles